First Quarter 2022 Financial Results

Tuesday, May 10, 2022

Nasdaq: EXEL





Today's Agenda

Introduction	Susan Hubbard EVP, Public Affairs and Investor Relations
First Quarter 2022 Highlights	Michael M. Morrissey, Ph.D. President and CEO
Financial Results & Guidance	Chris Senner EVP and CFO
Commercial Update	PJ Haley EVP, Commercial
Development Update	Vicki Goodman, M.D. EVP, Product Development & Medical Affairs and CMO
Discovery and Pipeline Update	Peter Lamb, Ph.D. EVP, Scientific Strategy and CSO

All Participants





Safe Harbor Statement

This presentation, including any oral presentation accompanying it, contains forward-looking statements, including, without limitation, statements related to: Exelixis' expectations for numerous expected top-line results for cabozantinib from COSMIC and CONTACT pivotal trials in 2022 to create opportunities for CABOMETYX label-expansion; Exelixis' planned launch of an XL092 pivotal trial program during the second guarter of 2022 and expansion of the XL092, XL102, XB002 clinical programs across new indications and combinations; Exelixis' discovery plans for 2022, including advancing up to five development candidates across both small molecules and biotherapeutics into preclinical development; Exelixis' 2022. financial guidance; Exelixis' anticipation that 1L RCC patients prescribed CABOMETYX in combination with nivolumab will receive therapy for approximately 1.5 years on average, thus driving a significantly longer treatment duration for CABOMETYX; Exelixis' belief that the broad adoption of CABOMETYX in combination with nivolumab in 1L RCC, lack of significant competitive impact and positive prescriber experience, taken together with the momentum of the business, position CABOMETYX well for continued growth throughout 2022; Exelixis' plans and the potential for continued growth of CABOMETYX through lifecycle expansion and the opportunity, pending data and approval, to bring CABOMETYX to many more patients in need of additional treatment options; Exelixis' East Coast expansion plans, including occupation of intermediate-term office space in King of Prussia, Pennsylvania in July 2020 and a potential long-term build-to-suite site nearby, and the opportunity to create a bicoastal presence across two biotechnology hubs operating as one team focused on Exelixis' mission; anticipated cabozantinib clinical program milestones and related timelines in 2022, including multiple data readouts from COSMIC and CONTACT trials and completion of enrollment for CONTACT-02; Exelixis' expectations regarding the clinical and therapeutic potential of XL092, including its potentially improved safety profile, to set new standards of care with novel treatment regimens; Exelixis' expectations regarding the clinical and therapeutic potential of XB002 and belief that the amended collaboration agreement with Iconic creates an opportunity for a potential TFtargeting franchise; Exelixis' expectations regarding the clinical and therapeutic potential of XL102 and belief that XL102 has the potential to be best-in-class due to the combination of selectivity, potency and oral bio-availability, as well as Exelixis' plans to move the ongoing QUARTZ-101 phase 1 trial into both single-agent and combination expansion cohorts; Exelixis' expectations regarding the clinical and therapeutic potential of XL114; Exelixis' plans to present phase 1 clinical updates for XL092, XB002 and XL102 at medical conferences in the second half of 2022, as well as for cabozantinib presentations at the 2022 ASCO Annual Meeting; Exelixis' plans for future growth of its discovery footprint with expanded laboratory capacity at the Alameda campus and on the East Coast with a potential new laboratory site in Pennsylvania; Exelixis' business development plans to access novel targets, capabilities and technologies to complement and accelerate ongoing biotherapeutics and small molecule strategies, as well as assess potential investment opportunities in late preclinical- and early clinical-stage assets that have the potential to address significant solid tumor populations; and Exelixis' anticipated milestones for 2022 and potential for multiple growth drivers towards becoming a multi-product oncology company serving cancer patients on a global scale. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis' and its partners' ability to obtain or maintain coverage and reimbursement for these products; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products; the level of costs associated with Exelixis' commercialization, research and development, in-licensing or acquisition of product candidates, and other activities; Exelixis' ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so; the availability of data at the referenced times; the potential failure of cabozantinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and/or efficacy in clinical testing; uncertainties inherent in the drug discovery and product development process; Exelixis' dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other Exelixis products; Exelixis' dependence on third-party vendors for the development, manufacture and supply of its products and product candidates; Exelixis' ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis' marketed products; changes in economic and business conditions, including as a result of the COVID-19 pandemic and other global events; and other factors discussed under the caption "Risk Factors" in Exelixis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2022, and in Exelixis' future filings with the SEC. All forward-looking statements in this presentation are based on information available to Exelixis as of the date of this presentation, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

This presentation includes certain non-GAAP financial measures as defined by the SEC rules. As required by Regulation G, we have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in the appendix.



First Quarter 2022 Highlights

Michael M. Morrissey, Ph.D.

President and CEO



Strong First Quarter of 2022 with Continued Growth of Cabozantinib Business and Advancement of Diversified Therapeutic Pipeline



CABOMETYX[®] business growth continues to fund our next-generation therapies

- CABOMETYX maintained status as leading TKI in RCC
- 37% year-over-year cabozantinib franchise revenue growth in Q1'22 vs Q1'21
- Sixth consecutive quarter of TRx growth

Multiple Development milestones on track for this year

- Emerging bicoastal development team across Alameda HQ and EXEL East
- Top-line results expected from COSMIC and CONTACT pivotal trials for cabozantinib
- Pipeline of clinical compounds XL092, XB002, XL102 and XL114 advancing through phase 1
- Initiation of XL092 pivotal trial program expected in Q2 2022

Advancing robust EXEL Discovery network and business development activities

- 10 programs advancing through internal and collaborative efforts
- Up to five development candidates anticipated across small molecules and biotherapeutics in 2022



TKI = tyrosine kinase inhibitor RCC = renal cell carcinoma TRx = total prescriptions


Financial Results & Guidance

Chris Senner EVP and CFO



Q1'22 Total Revenues

(See press release at www.exelixis.com for full details)



Q1'22 Notes

- \$310.3M in net product revenues
- Decrease in license revenues vs. Q4'21 primarily due to recognition of \$100M Ipsen milestone in Q4'21 for achieving \$400M in cumulative ex-US and ex-Canada net sales over 4 consecutive quarters
- Q1'22 collaboration services revenues primarily consist of development cost reimbursements from Ipsen and Takeda




Amounts may not sum due to rounding.

6

Q1'22 R&D Expenses

(See press release at www.exelixis.com for full details)



Amounts may not sum due to rounding.

A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.


*License and other collaboration costs include upfront, option exercise, program initiation, development milestone fees, and other fees; asset acquisition costs; and R&D funding for our collaboration and licensing agreements and assets purchase agreements.




7

Q1'22 SG&A Expenses

(See press release at www.exelixis.com for full details)







Amounts may not sum due to rounding. A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.

GAAP Financial Highlights: Q1'22

(in millions, except per share amounts)


	<u>Q1'21</u>	<u>Q4'21</u>	<u>Q1'22</u>	YoY Delta	QoQ Delta
Total revenues	\$270.2 M	\$451.1 M	\$356.0 M	+32%	-21%
Cost of goods sold	\$13.2 M	\$12.9 M	\$13.2 M	+0%	+2%
R&D expenses	\$159.3 M	\$222.3 M	\$156.7 M	-2%	-30%
SG&A expenses	\$102.4 M	\$99.3 M	\$102.9 M	+1%	+4%
Total operating expenses	\$274.8 M	\$334.5 M	\$272.7 M	-1%	-18%
Other income, net	\$2.6 M	\$1.4 M	\$2.0 M	-23%	+44%
Income tax provision (benefit)	(\$3.6) M	\$22.9 M	\$16.7 M	n/a	-27%
Net income	\$1.6 M	\$95.2 M	\$68.6 M	n/a	-28%
Net income per share, diluted	\$0.00	\$0.29	\$0.21	n/a	-28%
Ending cash and investments ⁽¹⁾	\$1,564.1 M	\$1,854.9 M	\$1,988.9 M	+27%	+7%

9



Q1'22 Net Income

(See press release at www.exelixis.com for full details)




Q1'22 Notes

- GAAP net income of \$68.6M
- Decrease in GAAP net income vs. Q4'21 primarily due to lower license revenues
- Non-GAAP net income of \$83.9M (excludes stock-based compensation expenses, net of tax effect)



Q1'22 Diluted Earnings Per Share

(See press release at www.exelixis.com for full details)





Non-GAAP Financial Highlights: Q1'22

(in millions, except per share amounts)

	<u>Q1'21</u>	<u>Q4'21</u>	<u>Q1'22</u>	YoY Delta	QoQ Delta
Total revenues	\$270.2 M	\$451.1 M	\$356.0 M	+32%	-21%
Cost of goods sold	\$13.2 M	\$12.9 M	\$13.2 M	0%	+2%
R&D expenses ^{(a)(b)}	\$146.9 M	\$213.2 M	\$147.8 M	+1%	-31%
SG&A expenses ^{(a)(b)}	\$80.1 M	\$85.2 M	\$92.0 M	+15%	+8%
Total operating expenses (a)(b)	\$240.2 M	\$311.3 M	\$253.0 M	+5%	-19%
Other income, net	\$2.6 M	\$1.4 M	\$2.0 M	-23%	+44%
Income tax provision ^(a)	\$4.2 M	\$27.9 M	\$21.1 M	+406%	-24%
Net income ^(a)	\$28.5 M	\$113.3 M	\$83.9 M	+195%	-26%
Net income per share, diluted ^(a)	\$0.09	\$0.35	\$0.26	+189%	-26%
Ending cash and investments ^(c)	\$1,564.1 M	\$1,854.9 M	\$1,988.9 M	+27%	+7%

Amounts may not sum due to rounding.

12

(a) A reconciliation of our GAAP to non-GAAP financial results is at the end of this presentation.

^(b) Amounts reflect non-GAAP adjustment before tax effect.

^(c) Cash and Investments is composed of cash, cash equivalents, restricted cash equivalents and investments.



Fiscal Year 2022 Financial Guidance*

	Guidance (Provided February 17, 2022)				
Total Revenues	\$1.525B - \$1.625B				
Net Product Revenues	\$1.325B - \$1.425B				
Cost of Goods Sold 5% - 6% of net product revenues					
R&D Expenses	\$725M - \$775M Includes \$45M in non-cash stock-based compensation				
SG&A Expenses	\$400M - \$450M Includes \$50M in non-cash stock-based compensation				
Tax Rate	20% - 22%				



Commercial Update

PJ Haley

EVP, Commercial





CABOMETYX: Continued Momentum in Q1 2022

Strong commercial execution continued in Q1 2022

- >\$310M Net Product Revenues*
- +11% TRx (Q1'22 vs Q4'21)
- CABOMETYX remains the #1 prescribed TKI in RCC and 2L HCC pretreated with ICI
- DTC continues to provide incremental growth and becoming the standard of care in 2L

6 Years of Commercial Excellence for the CABOMETYX Franchise

2L = second-line TKI = tyrosine kinase inhibitor RCC = renal cell carcinoma

15


ICI = immune checkpoint inhibitor HCC = hepatocellular carcinoma DTC = differentiated thyroid cancer TRx = total prescriptions

Sources:

Internal Exelixis data IQVIA National Prescription Audit and BrandImpact data through March 2022 *Net Product Revenues include revenues of CABOMETYX and COMETRIQ.



CABOMETYX Prescription Volume Continued Growth in Q1'22




• 6 quarters of continued TRx growth

- Nearly doubling of 40 mg NPS since launch in January 2021
- Inflection in demand driven by continued NPS and refills in 1L setting (stable dynamics in 2L)
 - Q/Q TRx = +11% (Q1'22 vs Q4'21)

16



CABOMETYX Business Summary - #1 TKI in RCC



- CABOMETYX was the #1 prescribed TKI in RCC market in Q1'22
- Strong Q/Q TRx market share growth (Q1'22 vs Q4'21) driven by new patient starts and refills of CABOMETYX + nivolumab in 1L RCC
- TKI TRx market grew ~7% in Q1'22 relative to Q4'21



CABOMETYX: Strong Performance Across All Approved Indications

RCC	НСС	DTC
 Growth in CABOMETYX driven by 1L RCC	 New patient market share	 Strong launch execution
(in combination with nivolumab) CABOMETYX 1L RCC uptake is broad across patient	stable in Q1'22 Continues to be the most	drove rapid awareness and
risk groups and practice settings Despite broad use, we see opportunity for	prescribed TKI post-IO	2L adoption CABOMETYX quickly
continued growth 2L monotherapy share remained stable in Q1'22	combination in 2L+ setting	established as a SOC in 2L

Broad adoption positions CABOMETYX for continued growth

1L = first-line 2L = second-line


18

HCC = hepatocellular carcinoma *DTC* = *differentiated thyroid cancer* RCC = renal cell carcinoma TKI = tyrosine kinase inhibitor

IO = *immunotherapy* SOC = standard of care Source: Internal Exelixis data

EXELIXIS IQVIA National Prescription Audit and BrandImpact data through March 2022

Cabozantinib Poised for Continued Growth Through Lifecycle Expansion



1L = first-lineMTC = medullary thyroid cancer2L = second-lineaHCC = advanced hepatocellular carcinomaRCC = renal cell carcinomaDTC = differentiated thyroid cancer

19

mCRPC = metastatic castration-resistant prostate cancer NSCLC = non-small cell lung cancer



Development Update

Vicki Goodman, M.D.

EVP, Product Development & Medical Affairs and CMO



Progress Report Across Development Organization

EXEL East: update on organizational expansion to East Coast

- As announced in early 2022, developing a presence in Philadelphia area seeking to access talent across both coasts of the U.S. to support rapidly expanding development activities
- Recently signed lease for intermediate-term office space in King of Prussia, Pennsylvania convenient and accessible location for Greater Philadelphia/Central New Jersey biopharma talent base
 - Space for approximately 140 office-based employees
 - Expected to occupy the space by July 2022
 - Recently launched recruitment campaign to raise awareness of our presence in Philadelphia area
- Identified potential long-term, build-to-suit site of approximately 200K sq. ft. in King of Prussia
- Begun hiring to open roles within EXEL East Development organization




Three Phase 3 Readouts for Cabozantinib Expected in 2022

Study	Setting	Latest Status Update	Next Milestone(s)
COSMIC 313 Cabozantinib + Nivolumab + Ipilimumab	1L aRCC IMDC intermediate and poor risk	Clinical cutoff for primary analysis of PFS achieved	Top-line results expected July 2022
COSMIC 021 Cabozantinib + Atezolizumab	Multiple Tumors	Q1 2022: Presented data from Cohort 16 (CRC) at ASCO GI	Initiate Phase 3 program for XL092 based on data from COSMIC-021; Present data from additional cohorts in 2022
CONTACT-01 Cabozantinib + Atezolizumab	Metastatic NSCLC after ICI and platinum chemo	Global enrollment completed in November 2021	Interim readout of OS primary endpoint expected in 2H 2022
CONTACT-02 Cabozantinib + Atezolizumab	mCRPC after one NHT	Actively enrolling globally	Enrollment completion expected 2022
CONTACT-03 Cabozantinib + Atezolizumab	aRCC w/progression during or following ICI	Global enrollment completed in December 2021	Readout of the PFS primary endpoint expected in 2H 2022

1L = first-line OS = overall survival PFS = progression-free survival NHT = novel hormonal therapy aRCC = advanced renal cell carcinoma CRC = colorectal cancer NSCLC = non-small cell lung cancer ICI = immune checkpoint inhibitor IMDC = International Metastatic RCC Database Consortium ASCO GI = American Society of Clinical Oncology Gastrointestinal Symposium mCRPC = metastatic castration-resistant prostate cancer



Extensive Development Plan Supported by XL092's Differentiated Clinical Profile and Potentially Improved Safety Profile – Progressing Toward Registrational Studies




Combination Approaches

Expanding Beyond ICI-TKI Success to set new standards of care with triplet and novel combinations based on indication, therapeutic setting and line

EXEL

XL092: STELLAR-002 Phase 1b Study Ongoing

Exelixis-sponsored Study in Collaboration with Bristol Myers Squibb



XL092 single agent and standard of care ICI combination therapies

Dosing initiated for XL092 + nivolumab combination in GU malignancies; protocol amendment in process to replace BEMPEG triplet with alternative triplet combination


1L = first-line 2L = second-line UC = urothelial carcinoma

ccRCC = clear cell renal cell carcinoma nccRCC = non-clear cell RCC ICI = immune checkpoint inhibitor mCRPC = metastatic castration-resistant prostate cancer NHT = novel hormonal therapy GU = genitourinary



STELLAR-303: Pivotal Study of XL092 in 3L+ CRC to Initiate in Q2 2022

Exelixis-sponsored Study with Drug Supply Agreement with Genentech/Roche



Stratification Factors

- Geographical region (Asia vs. other)
- Documented RAS status (wild type vs. mutant)
- Left vs. Right-sided disease

OS = overall survivalITT = intent to treatPFS = progression free survivalDOR = duration of responseORR = objective response rateQOL = quality of life

3L = third-line CRC = colorectal cancer RAS = rat sarcoma virus

Key Study Objectives

- **Primary:** OS (ITT RAS wild type)
- Additional: PFS, ORR, DOR, QOL



XB002: Building the Foundation for a TF-Targeting Oncology Franchise



Tissue factor is normally involved in mediating coagulation

Overexpressed in many solid tumors: TF-ADC approach clinically validated in cervical cancer

XB002 TF antibody has significant advantages over 1st generation TF-targeted therapies

- Improved preclinical TI: binder non-competitive with Factor VII, next-generation linker-payload
- Early clinical experience: excellent stability of intact ADC and low free payload concentration; early safety data are encouraging, including no bleeding events observed to date

JEWEL-101: Phase 1 Clinical Study OngoingDose EscalationXB002 Single-Agent
(Advanced Solid Tumors)XB002 Combination
(herapy
(Advanced Solid Tumors)

XB002 Development Plans

- Expand development as monotherapy and in combination with ICIs and other targeted therapies across wide range of tumor types
- Dec'21 amended agreement with Iconic Therapeutics creates opportunity for potential TF-targeting oncology franchise



TF = tissue factor ADC = antibody-drug conjugate TI = therapeutic index ICI = immune checkpoint inhibitor

NSCLC = non-small cell lung cancer mCRPC = metastatic castrate resistant prostate cancer TNBC = triple negative breast cancer HR+ BC = hormone receptor positive breast cancer


XL102: Covalent Orally Available CDK7 Inhibitor with Broad Potential in Oncology



27

CDK7 regulates cell cycle progression and transcription


- Potential for activity in CDK4/6 inhibitor resistant tumors combination with targeted therapies
 XL102 has the potential to be best-in-class due to the combination of selectivity, potency and oral bioavailability
 - Early clinical experience: near complete target engagement in PBMCs





HR+ BC = hormone receptor positive breast cancer mCRPC = metastatic castration-resistant prostate cancer

XL114: Inhibitor of MALT1 Activation and B-Cell Lymphoma Cell Growth



XL114 inhibits the CBM signaling pathway that promotes lymphocyte survival and proliferation

- Acts downstream of BTK
- Activity in BTK resistant lymphoma models and subsets of BCL where BTK inhibitors are not active

XL114 phase 1 trial initiated in April 2022

Source: Young and Staudt, Cancer Cell 22 (2012)

ABC = activated B-cell subtype DLBCL = diffuse large B-cell lymphoma BCL = B-cell lymphoma NHL = non-Hodgkin's lymphoma IND = Investigational New Drug application BTK = Bruton's tyrosine kinase

CBM = *CARD11-BCL10-MALT1*



Cabozantinib Oral Presentations at 2022 ASCO Annual Meeting Include Two COSMIC-021 Cohorts and a Phase 2 IST Evaluating Cabozantinib + Pembrolizumab

2022 ASCO® ANNUAL MEETING

ASCO 2022 Annual Meeting to be held online and in-person in Chicago from June 3-7th Thirteen total presentations for cabozantinib from Exelixis and network of investigator-sponsored studies

Cabozantinib presentations from Phase 1b COSMIC-021 trial

- Abstract 4504 Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study.
- Abstract 9005 Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

Phase 2 IST evaluating cabozantinib + pembrolizumab

 Abstract 6008 - A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC).



Discovery and Pipeline Update

Peter Lamb, Ph.D.

EVP, Scientific Strategy and CSO



Exelixis Pipeline Beyond Cabozantinib a Balanced Mix of Small Molecules and Biotherapeutics

Program Name	Mechanism	Discovery / Preclinical	IND	Phase 1a	Phase 1b	Phase 2 / 3
XL092	Next-generation TKI targeting MET,	/VEGFR/AXL/MER				
XB002	Next-generation TF-targeting ADC					
XL102	Potent, selective, orally bioavailable	e CDK7 inhibitor				
XL114	CARD11-Bcl10-MALT1 pathway inh	ibitor				
XB010	Next-generation 5T4 targeting ADC					
Aurigene Collaboration Programs	CDK12 and MALT1 inhibitors					
Invenra Collaboration Programs	PD-L1 + CD47 and PD-L1 + NKG2A					
StemSynergy Collaboration Programs	CK1 α activators and selective Notch	n inhibitors		10 discover	i programs i	n progress with
STORM Therapeutics Collaboration Program	ADAR1			the pote	ntial to advo	ince up to 5
Exelixis Discovery Programs	G9a inhibitors			compounds i		al development
Biotherapeutics Programs Invenra, NBE Therapeutics, Catalent, GamaMabs WuXi & Adagene Collaborations	AMHR2, ROR1/2, TF, DLL3					

TKI = tyrosine kinase inhibitor CDK7 = cyclin-dependent kinase 7 CK1α = casein kinase 1 alpha

TF = tissue factor ADC = antibody-drug conjugate IND = Investigational New Drug application CDK12 = cyclin-dependent kinase 12 NKG2A = natural killer cell receptor group 2A ADAR1 = adenosine deaminase 1



Continued Acceleration of Our Pipeline Through Internal Growth and Business Development Activities

Significantly expanding internal discovery footprint with new laboratories at Alameda HQ

- New laboratory building in 2021 enabled added capacity and new capabilities for small molecule discovery efforts
- Further laboratory expansion underway in Alameda to accommodate future growth in 2022 and beyond
- Site located in Pennsylvania for laboratory expansion on the East Coast to tap into locally available talent pool and complement newly opened EXEL East Development offices

Broad business development efforts ongoing

- To provide access to novel targets, capabilities and technologies to complement and accelerate ongoing biotherapeutics and small molecule strategies
- Assessing potential investment opportunities in late preclinical and early clinical assets







Michael M. Morrissey, Ph.D.

President and CEO



Execution Across All Facets of Our Business in Q1 2022

- Significant progress across pipeline, clinical development and commercial activities
- Potential for multiple growth drivers in 2022 to put Exelixis in a position to help many more cancer patients
- Focused on leveraging our vision, determination and resources to become a multi-product oncology company serving cancer patients on a global scale



Anticipated Milestones for 2022

Program		Milestone
COSMIC-313		Report top-line results in July 2022 for phase 3 trial of triplet combination cabozantinib + nivolumab + ipilimumab vs nivolumab + ipilimumab in 1L RCC
CONTACT-01/-02/-03		Report initial data in the second half of 2022 from pivotal trials of cabozantinib + atezolizumab in forms of NSCLC (CONTACT-01) and RCC (CONTACT-03). Complete enrollment in pivotal trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02)
COSMIC-313 Image: Report top-line results in July 2022 for phase 3 trial of triplet combination cabozantinib + nivolumab + ipilimumab vs nivolumating in JL RCC CONTACT-01/-02/-03 Image: Report initial data in the second half of 2022 from pivotal trials of cabozantinib + atezolizumab in forms of NSCLC (CONTACT-02) and RCC (CONTACT-03). Complete enrollment in pivotal trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02) COSMIC-021 Image: Present data from CRC cohort of phase 1b trial of cabozantinib + atezolizumab at ASCO GI, on Jan. 22, 2022 COSMIC-021 Image: Present data from additional cohorts of phase 1b evaluating cabo + atezo and single-agent cabo at ASCO Annual Meeting NL092 Initiate STELLAR-303 global phase 3 pivotal trial of XL092 + atezolizumab in 3L+ CRC in Q2 2022 NL092 Initiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination therapies XB002 Expand and report clinical updates from phase 1b STELLAR-001/-002 trials into new tumor types and combination therapies XL102 Initiate cohort expansion of ongoing phase 1 study across combination regimens and tumor types, based on early clinical sign XL114 Imitiate dosing in phase 1 trial of XL114 in patients with NHL		
	Present data from additional cohorts of phase 1b evaluating cabo + atezo and single-agent cabo at ASCO Annual Meeting	
		Initiate STELLAR-303 global phase 3 pivotal trial of XL092 + atezolizumab in 3L+ CRC in Q2 2022
XL092	AIC-313Report top-line results in July 2022 for phase 3 trial of triplet combination cabozantinib + nivolumab + ipilimumab vs nivolumabAIC-313Report initial data in the second half of 2022 from pivotal trials of cabozantinib + atezolizumab in forms of NSCLC (CONTACT-01) and RCC (CONTACT-03). Complete enrollment in pivotal trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02)ACT-01/-02/-03Present data from CRC cohort of phase 1b trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02)AIC-021Present data from CRC cohort of phase 1b trial of cabozantinib + atezolizumab at ASCO GI, on Jan. 22, 2022AIIC-021Initiate STELLAR-303 global phase 3 pivotal trial of XL092 + atezolizumab in 3L+ CRC in Q2 2022Initiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination regimensInitiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination therapiesInitiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination therapiesInitiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination therapiesInitiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination therapiesInitiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination therapiesInitiate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination therapiesInitiate additional pivotal trials of XL092 as monotherapy and in combination with ICIs and other targeted therapies, broadly across tumorInitiate cohort expansion of ongoing phase 1 study across combinat	
COSMIC-313Image: ipilimumab in 1L RCCCONTACT-01/-02/-03Image: Report initial data in the second and RCC (CONTACT-03). Complete and RCC	Expand and report clinical updates from phase 1b STELLAR-001/-002 trials into new tumor types and combination therapies	
CONTACT-01/-02/-03 Image: and RCC (CONTACT-03). Complete enrollment in pivotal trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02) COSMIC-021 Image: Antiperiod Contract - 03). Complete enrollment in pivotal trial of cabozantinib + atezolizumab at ASCO GI, on Jan. 22, 2022 Image: COSMIC-021 Image: Antiperiod Contract - 03). Complete enrollment in pivotal trial of cabozantinib + atezolizumab at ASCO GI, on Jan. 22, 2022 Image: COSMIC-021 Image: Present data from CRC cohort of phase 1b trial of cabozantinib + atezolizumab at ASCO GI, on Jan. 22, 2022 Image: COSMIC-021 Image: Present data from additional cohorts of phase 1b evaluating cabo + atezo and single-agent cabo at ASCO Annual Meeting Image: Cosmic Cosmicosmic Cosm		
	VI 102	
COSMIC-313 ipilimumab in 1L RCC CONTACT-01/-02/-03 a Report initial data in the second half of 2022 from pivotal trials of cabozantinib + atezolizumab in forms of NSCLC (CONTACT-02) and RCC (CONTACT-03). Complete enrollment in pivotal trial of cabozantinib + atezolizumab in mCRPC (CONTACT-02) COSMIC-021 Imitate from CRC cohort of phase 1b trial of cabozantinib + atezolizumab at ASCO GI, on Jan. 22, 2022 Imitate STELLAR-303 global phase 3 pivotal trial of XL092 + atezolizumab in 3L+ CRC in Q2 2022 Imitate additional pivotal trials of XL092 global phase 3 program across various tumor types and combination regimens Expand and report clinical updates from phase 1b STELLAR-001/-002 trials into new tumor types and combination therapies XB002 Expand development of XB002 as monotherapy and in combination with ICIs and other targeted therapies, broadly across tu types, including NSCLC, UC, HNSCC, mCRPC, TNBC, HR+ BC, pancreatic, esophageal, ovarian and cervical cancers XL102 Initiate cohort expansion of ongoing phase 1 study across combination regimens and tumor types, based on early clinical sign XL114 Imitiate dosing in phase 1 trial of XL114 in patients with NHL		
XL114		Initiate dosing in phase 1 trial of XL114 in patients with NHL
Preclinical		Advance up to five new development candidates across multiple modalities / mechanisms of small molecules and biologics

1L = first-lineNSCLC = non-small cell lung cancermC3L = third-lineUC = urothelial carcinomaHNRCC = renal cell carcinomaICI = immune checkpoint inhibitorHRCRC = colorectal cancerTNBC = triple negative breast cancerNH

35

mCRPC = metastatic castration-resistant prostate cancer HNSCC = head and neck squamous cell carcinoma HR+ BC = hormone receptor positive breast cancer NHL = non-Hodgkin's lymphoma



Q&A Session





First Quarter 2022 Financial Results

Tuesday, May 10, 2022

Nasdaq: EXEL






Financial Appendix



Collaboration Revenues Detail

(See press release at www.exelixis.com for full details)



Q1'21 – Q1'22 Notes


- Q1'22 cabozantinib royalties to Exelixis of \$27.0M
- Genentech collaboration:
 - Q1'22 ex-US COTELLIC® royalties \$1.6M
 - Q1'22 US COTELLIC profit share \$2.1M
- Significant milestone revenues recognized by quarter:
 - Q1'22: No new milestone license revenues recognized
 - Q4'21: Ipsen achievement of \$400M in cumulative ex-US and ex-Canada net sales over 4 consecutive quarters
 - Q3'21: Takeda 1L RCC (9ER) first commercial sale
 - Q2'21: Ipsen MAA filing DTC (COSMIC-311)
 - Q1'21: No new milestone license revenues recognized



1L = first-line RCC = renal cell carcinoma DTC = differentiated thyroid cancer

Ipsen Royalties

(See press release at www.exelixis.com for full details)





GAAP to Non-GAAP Reconciliation

(in millions, except per share amounts)

Non-GAAP Financial Measures

To supplement Exelixis' financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis uses certain non-GAAP financial measures in this presentation and the accompanying tables. This presentation and the tables that follow present certain financial information on a GAAP and a non-GAAP basis for Exelixis for the periods specified, along with reconciliations of the non-GAAP financial measures presented to the most directly comparable GAAP measures. Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that each of these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare Exelixis' results from period to period, and to identify operating trends in Exelixis' business. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.

These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis' business. Reconciliations between GAAP and non-GAAP results are presented in the tables that follow.

	 Q1'21	 Q2'21	 Q3'21	 24'21	 21'22
Research and development expenses reconciliation:					
GAAP Research and development expenses	\$ 159.3	\$ 148.8	\$ 163.4	\$ 222.3	\$ 156.7
Stock-based compensation expenses ⁽¹⁾	 (12.4)	 (13.7)	 (11.5)	 (9.1)	 (8.9)
Non-GAAP Research and development expenses	\$ 146.9	\$ 135.1	\$ 151.9	\$ 213.2	\$ 147.8
Selling, general and administrative expenses reconciliation:					
GAAP Selling, general and administrative expenses	\$ 102.4	\$ 98.5	\$ 101.6	\$ 99.3	\$ 102.9
Stock-based compensation expenses ⁽¹⁾	 (22.3)	 (14.4)	 (22.5)	 (14.1)	 (10.9)
Non-GAAP Selling, general and administrative expenses	\$ 80.1	\$ 84.1	\$ 79.1	\$ 85.2	\$ 92.0
Operating expenses reconciliation:					
GAAP Operating expenses	\$ 274.8	\$ 262.2	\$ 276.8	\$ 334.5	\$ 272.7
Stock-based compensation - Research and development expenses ⁽¹⁾	(12.4)	(13.7)	(11.5)	(9.1)	(8.9)
Stock-based compensation - Selling, general and administrative expenses ⁽¹⁾	 (22.3)	 (14.4)	 (22.5)	 (14.1)	 (10.9)
Non-GAAP Operating expenses	\$ 240.2	\$ 234.1	\$ 242.8	\$ 311.3	\$ 253.0
Income tax provision					
GAAP Income tax provision (benefit)	\$ (3.6)	\$ 28.8	\$ 15.1	\$ 22.9	\$ 16.7
Income tax effect of stock-based compensation - Research and development ⁽²⁾	2.8	3.0	2.6	2.0	2.0
Income tax effect of stock-based compensation - Selling, general and administrative ⁽²⁾	 5.0	 3.2	 5.1	 3.1	 2.5
Non-GAAP Income tax provision	\$ 4.2	\$ 35.0	\$ 22.7	\$ 27.9	\$ 21.1



GAAP to Non-GAAP Reconciliation (continued)

(in millions, except per share amounts)

	 21'21	 Q2'21	 23'21	(Q4'21	 1'22
Net Income reconciliation:						
GAAP Net Income	\$ 1.6	\$ 96.1	\$ 38.2	\$	95.2	\$ 68.6
Stock-based compensation - Research and development ⁽¹⁾	12.4	13.7	11.5		9.1	8.9
Stock-based compensation - Selling, general and administrative ⁽¹⁾	22.3	14.4	22.5		14.1	10.9
Income tax effect of the stock-based compensation adjustments ⁽²⁾	 (7.8)	 (6.2)	 (7.6)		(5.0)	 (4.4)
Non-GAAP Net Income	\$ 28.5	\$ 117.9	\$ 64.5	\$	113.3	\$ 83.9
Net Income per share, diluted:						
GAAP Net Income per share, diluted	\$ 0.00	\$ 0.30	\$ 0.12	\$	0.29	\$ 0.21
Stock-based compensation - Research and development ^[1]	0.04	0.04	0.04		0.03	0.03
Stock-based compensation - Selling, general and administrative ⁽¹⁾	0.07	0.04	0.07		0.04	0.03
Income tax effect of the stock-based compensation adjustments ⁽²⁾	 (0.02)	 (0.02)	 (0.02)		(0.02)	 (0.01)
Non-GAAP Net Income per share, diluted	\$ 0.09	\$ 0.37	\$ 0.20	\$	0.35	\$ 0.26
Weighted-average shares used to compute GAAP net income per share, diluted	321.3	322.9	322.0		323.2	323.3

⁽¹⁾ Non-cash stock-based compensation expense used for GAAP reporting in accordance with ASC 718.

⁽²⁾ Income tax effect on the non-cash stock-based compensation expense adjustments.



Collaboration Revenues

(in millions)

Partner	Compound	Description		Q1'21		Q2'21		Q3'21		Q4'21	(Q1'22
Roche (Genentech)	COTELLIC	Profit Share & Royalties on Ex-U.S. sales	\$	2.7	\$	2.9	\$	3.3	\$	3.1	\$	3.8
Partner Royalties	Cabozantinib	Royalties on ex-U.S.		23.8		24.9		27.1		29.3		27.0
Milestones:												
Ipsen	Cabozantinib	Amortization of Milestones Triggered prior to Q1'18		(0.2)		0.1		0.3		0.2		(0.1
Ipsen	Cabozantinib	\$50M M/S 1L RCC Approval		(0.1)		-		0.1		0.1		-
Ipsen	Cabozantinib	\$40M M/S EMA 2L HCC Approval		(0.1)		-		0.1		0.1		-
Ipsen	Cabozantinib	\$12.5M M/S MAA filing DTC		-		11.8		-		-		-
Ipsen	Cabozantinib	\$100M Net sales 4 consecutive quarters >\$400M		-		-		-		100.0		-
Takeda	Cabozantinib	\$16M M/S Japan regulatory filing 2L RCC		0.3		0.3		0.1		0.1		0.3
Takeda	Cabozantinib	\$26M M/S 1st Commercial Sale in Japan - 2L RCC		0.4		0.3		0.1		0.1		0.3
Takeda	Cabozantinib	\$10M M/S Japan regulatory filing 1L RCC		0.1		-		-		-		-
Takeda	Cabozantinib	\$15M M/S 1st Commercial Sale in Japan - 2L HCC		0.1		0.1		-		-		0.1
Takeda	Cabozantinib	\$10M M/S Additional Indication/Initiation Phase 3		0.1		-		-		-		-
Takeda	Cabozantinib	\$5M M/S Additional Indication/Initiation Phase 3		-		-		-		-		-
Takeda	Cabozantinib	\$20M M/S 1st Commercial Sale in Japan - 1L RCC		-		-		18.8		-		0.1
		Subtotal Milestones	\$	0.6	\$	12.9	\$	19.7	\$	100.7	\$	0.7
		Milestones License revenues	\$	-	\$	10.8	\$	18.1	\$	100.0	\$	-
		Milestones Collaboration services revenues	\$	0.6	\$	2.1	\$	1.6	\$	0.7	\$	0.7
R&D Reimbursements & Ot	her:											
Ipsen	Cabozantinib	R&D reimbursement and Product Supply	\$	12.1	\$	56.0	\$	12.0	\$	11.8	\$	10.3
Ipsen	Cabozantinib	\$200M Upfront fee		(0.3)		0.1		0.4		0.3		(0.2
Takeda	Cabozantinib	R&D reimbursement and Product Supply		3.0		3.0		1.6		2.5		2.7
Takeda	Cabozantinib	\$50M Upfront fee		0.2		0.1		-		-		0.1
Daiichi Sankyo & royalties	MR CS-3150/MINNEBRO			1.0		0.9		1.2		0.6		1.3
		Subtotal R&D Reimbursments & Other	\$	15.9	\$	60.2	\$	15.2	\$	15.3	\$	14.3
Total License revenues			\$	27.5	\$	39.6	\$	49.7	\$	133.1	\$	32.1
Total Collaboration servic	es revenues		-	15.5	-	61.3	-	15.6	-	15.4	-	13.6
TOTAL COLLABORATION REV	VENUES		Ś	43.0	\$	100.9	Ś	65.3	Ś	148.5	Ś	45.7



First Quarter 2022 Financial Results

Tuesday, May 10, 2022

Nasdaq: EXEL



